Future challenges for IPF
Carlo Vancheri discusses future challenges for IPF
The first thing is that we should try to understand the pathogenesis of the disease and the pathogenesis of acute exacerbation, first of the disease. Because right now, as you said before talking about the pathobiology, we have a long list of mechanisms and that they are all involved. The problem is to put all of them together and this is very, is very complicated because IPF is a very peculiar disease where we have working all together, we have risk factors, we have a genetic background, we have aging and it’s very difficult to understand the involvement and the, and how important are all these factors.
And as I said before, the other important hope for the future is to, to have and to develop a good biomarker for the prevention of acute exacerbation but also that could help in the diagnosis and also some prognostic markers, why not? And, in the end, also I think that we need biomarkers, that could be biological but also clinical biomarkers, that may help us identifying those subgroups of patients that will respond in a different way to treatment. You mentioned, you know, the TOLLIP, but probably there are many other subgroups of patients that, because we know that in our everyday clinic that there are some patients that respond very well to treatment and some other they did not respond, some patient that they have more side effects compared to others. So, we really need that to identify these subgroups of patients. These are my hopes for the future.